NotableResults posted: Sep 23, 2026Show 5 more changesShow less
Primary endpoints revised (2)
Eligibility criteria expanded, about 29 words
Secondary endpoints revised (8)
Study sites revised (99)
Study arms: 6 to 4
MinorStudy sites revised (99)v35
MinorStudy sites: 98 to 99v34
StoppedTrial status: Active, Not Recruiting to TerminatedSponsor's reason: Sponsor decision
Study sites: 171 to 98
Primary completion date changed from estimate of Jul 20, 2026 to Sep 2, 2025
Study completion date changed from estimate of Jul 27, 2026 to Sep 2, 2025
v33
MinorTrial status: Recruiting to Active, Not Recruiting
Enrollment target: estimated 230 to confirmed 85
Study sites: 179 to 171
v32
Show 30 earlier versionsHide 30 earlier versions
MinorRe-verified, no change to tracked fieldsv31
MinorSite details revised at 3 of 179 sitesv30
MinorStudy sites: 180 to 179v29
MinorPrimary completion date: Mar 18, 2026 to Jul 20, 2026
Study completion date: Mar 25, 2026 to Jul 27, 2026
Study sites revised (180)
v28
NotableTrial status: Active, Not Recruiting to Recruiting
Site details revised at 180 of 180 sites
v27
MinorTrial status: Recruiting to Active, Not Recruiting
Site details revised at 180 of 180 sites
v26
MinorSite details revised at 12 of 180 sitesv25
MinorSite details revised at 1 of 180 sitesv24
MinorSite details revised at 19 of 180 sitesv23
MinorStudy sites: 102 to 180v22
MinorStudy sites: 99 to 102v21
MinorStudy sites: 93 to 99v20
MinorStudy sites: 85 to 93v19
MinorStudy sites: 78 to 85v18
MinorStudy sites: 82 to 78v17
MinorStudy sites: 92 to 82v16
MinorStudy sites: 83 to 92v15
MinorStudy sites: 92 to 83v14
MinorStudy sites: 121 to 92v13
NotablePrimary completion date: Jul 21, 2025 to Mar 18, 2026
Study sites: 117 to 121
Study completion date: Aug 6, 2025 to Mar 25, 2026
v12
MinorStudy sites: 114 to 117v11
MinorStudy sites: 69 to 114
Start date: Aug 20, 2024 to Aug 28, 2024
Eligibility criteria expanded, about 36 words
v10
MinorStudy sites: 68 to 69v9
MinorStudy sites: 45 to 68v8
MinorStudy sites: 27 to 45v7
MinorStudy sites: 20 to 27v6
MinorStudy sites: 8 to 20v5
MinorStudy sites: 1 to 8v4
NotableTrial status: Not Yet Recruiting to Recruiting
Study sites: 0 to 1
v3
MinorStart date: Jul 27, 2024 to Aug 20, 2024v2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Adults 40 years of age and older with idiopathic pulmonary fibrosis (IPF) or 18 years and older with progressive pulmonary fibrosis (PPF) can participate in this study. Only people who have a chronic cough can take part. The purpose of this study is to find out how well BI 1839100 helps reduce coughing in people with IPF or PPF.
Participants who have IPF are put into 4 groups by chance. Participants in 3 groups get different doses of BI 1839100. Participants in 1 group get placebo. Placebo looks like BI 1839100 but does not contain any medicine. Participants take the treatment for 3 months. After 1 month of treatment, participants who take the highest dose will have coughing measured to find out if the medicine works. If it does not work, the study may be stopped. Participants who have IPF are in the study for slightly longer than 4 months. During this time, they visit the study site 7 times. This study will also measure the effects of BI 1839100 on coughing and lung function in a smaller group of people with PPF.
During the study, coughing is measured over 24 hours about once per month using a portable device given to participants to use during the study. Participants fill in questionnaires about their coughing. Doctors also perform breathing tests that measure how well the lungs are working at the site visits. Researchers compare the results between participants who take BI 1839100 and placebo. The doctors also regularly check participants' health and take note of any unwanted effects.